Literature DB >> 24496992

[Determination of tumor biological parameters in breast cancer: round robin testing for quality assurance].

S Liessem1, W Winkens, D Jonigk, R V Wasielewski, A Fisseler-Eckhoff, J Rüschoff, H-H Kreipe.   

Abstract

Round robin testing for quality assurance in the determination of the breast cancer biomarkers estrogen receptor (ER), progesterone receptor (PR) and epithelial growth factor receptor 2 (HER2) have been carried out in Germany for 13 years. As the first quality assurance trial worldwide tissue microarrays with 20 different breast cancer specimens were used. As a further innovation the challenges were split into a test part representing routine cases and a training part enriched with difficult borderline cases in order to uncover latent weaknesses in the participating laboratories. Certificates are issued based exclusively on the test part. Similar to NordiQC and UKNequas stained slides are assessed externally and the quality of staining and evaluation are considered separately. Since 2010 an additional internet-based trial without assessment of the staining quality is offered for ER and PR. Since the introduction of the round robin trials the numbers of participants (n = 200-250) and the success rates have steadily increased. The breast cancer quality assurance trial ranks first with regard to the number of participants in Germany. It could be demonstrated that regular participation in the round robin test leads to an improvement of staining results of ER, PR and HER2 and hence appears to be mandatory for maintaining quality standards. The use of fully automated immunohistochemical staining procedures has steadily increased and these are now used by approximately 50 % of participants.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24496992     DOI: 10.1007/s00292-013-1837-3

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  8 in total

1.  [Interlaboratory trial 2000 " Immunohistochemistry" of the German Society for Pathology and the Professional Association of German Pathologists].

Authors:  T Rüdiger; H Höfler; H-H Kreipe; H Nizze; U Pfeifer; H Stein; E Dallenbach; H-P Fischer; M Mengel; R Von Wasielewski; K Müller-Hermelink
Journal:  Pathologe       Date:  2003-01-17       Impact factor: 1.011

2.  Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists.

Authors:  Thomas Rüdiger; H Höfler; H-H Kreipe; H Nizze; U Pfeifer; H Stein; F E Dallenbach; H-P Fischer; M Mengel; R von Wasielewski; H K Müller-Hermelink
Journal:  Am J Surg Pathol       Date:  2002-07       Impact factor: 6.394

3.  [Interlaboratory trials for quality assurance of breast cancer biomarkers in Germany].

Authors:  C A Krusche; R von Wasielewski; J Rüschoff; A Fisseler-Eckhoff; H H Kreipe
Journal:  Pathologe       Date:  2008-07       Impact factor: 1.011

4.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

5.  Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial.

Authors:  Reinhard von Wasielewski; Michael Mengel; Birgitt Wiese; Thomas Rüdiger; Hans Konrad Müller-Hermelink; Hans Kreipe
Journal:  Am J Clin Pathol       Date:  2002-11       Impact factor: 2.493

Review 6.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

Authors:  D C Allred; J M Harvey; M Berardo; G M Clark
Journal:  Mod Pathol       Date:  1998-02       Impact factor: 7.842

7.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

8.  Proficiency testing of immunohistochemical biomarker assays in breast cancer.

Authors:  Reinhard von Wasielewski; Svenja Hasselmann; Josef Rüschoff; Annette Fisseler-Eckhoff; Hans Kreipe
Journal:  Virchows Arch       Date:  2008-10-29       Impact factor: 4.064

  8 in total
  1 in total

1.  [Determination of proliferation in breast cancer by immunohistochemical detection of Ki-67].

Authors:  M Christgen; W Winkens; H H Kreipe
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.